Michael De Vivo

Michael De Vivo

Company: BioXcel Therapeutics

Job title: Vice President, Neuroscience

Seminars:

Live Q&A 1:20 pm

Read more

day: Day One

BXCL501: Targeting Alpha2-Adrenrgic Receptors for Neuropsychiatric Symptoms 12:55 pm

• Stress activates Noradrenergic Signaling and may precipitate psychiatric symptoms • Alpha2-Adrenergic Receptors Regulate noradrenergic signaling • BXCL501 is designed to activate alpha2-adrenergic receptors and thereby alleviate the symptoms caused by overactive noradrenergic signaling • BXCL501 rapidly and effectively reduced agitation in patients with schizophrenia or bipolar disorderRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.